Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial
Salib M, Girerd S, Girerd N, Marz W, Scharnagl H, Massy ZA, Leroy C, Duarte K, Holdaas H, Jardine AG, Schmieder R, Fellstrom B, Lopez-Andres N, Rossignol P, Zannad F (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1007/s00392-021-01898-9
Abstract
Background Biomarkers of fibrosis are associated with outcome in several cardiovascular diseases. However, their relevance to chronic kidney disease and dialysis is uncertain, as it remains unclear how the kidneys and the dialysis procedure itself affect their elimination and degradation. We aimed to investigate the relationship of the blood levels of two markers associated with fibrosis: procollagen type I C-terminal pro-peptide (PICP) and galectin-3 (Gal-3) with mortality in dialysis patients.
Authors with CRIS profile
Involved external institutions
Université de Lorraine
France (FR)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Hôpital Ambroise-Paré
France (FR)
University of Oslo
Norway (NO)
University of Glasgow
United Kingdom (GB)
Uppsala University Hospital / Akademiska sjukhuset
Sweden (SE)
Universidad Pública de Navarra
Spain (ES)
France (FR)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Hôpital Ambroise-Paré
France (FR)
University of Oslo
Norway (NO)
University of Glasgow
United Kingdom (GB)
Uppsala University Hospital / Akademiska sjukhuset
Sweden (SE)
Universidad Pública de Navarra
Spain (ES)
How to cite
APA:
Salib, M., Girerd, S., Girerd, N., Marz, W., Scharnagl, H., Massy, Z.A.,... Zannad, F. (2021). Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-021-01898-9
MLA:
Salib, Madonna, et al. "Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial." Clinical Research in Cardiology (2021).
BibTeX: Download